特发性肺纤维化的血管受累。

IF 4.3 3区 医学 Q1 RESPIRATORY SYSTEM
ERJ Open Research Pub Date : 2024-11-25 eCollection Date: 2024-11-01 DOI:10.1183/23120541.00550-2024
Michele Mondoni, Rocco Rinaldo, Christopher J Ryerson, Cristina Albrici, Andrea Baccelli, Claudio Tirelli, Francesca Marchetti, Jacopo Cefalo, Giulia Nalesso, Giulia Ferranti, Fausta Alfano, Giovanni Sotgiu, Marco Guazzi, Stefano Centanni
{"title":"特发性肺纤维化的血管受累。","authors":"Michele Mondoni, Rocco Rinaldo, Christopher J Ryerson, Cristina Albrici, Andrea Baccelli, Claudio Tirelli, Francesca Marchetti, Jacopo Cefalo, Giulia Nalesso, Giulia Ferranti, Fausta Alfano, Giovanni Sotgiu, Marco Guazzi, Stefano Centanni","doi":"10.1183/23120541.00550-2024","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing and progressive interstitial lung disease of unknown aetiology with a pathogenesis still partly unknown. Several microvascular and macrovascular abnormalities have been demonstrated in the pathogenesis of IPF and related pulmonary hypertension (PH), a complication of the disease.</p><p><strong>Methods: </strong>We carried out a non-systematic, narrative literature review aimed at describing the role of the vasculature in the natural history of IPF.</p><p><strong>Results: </strong>The main molecular pathogenetic mechanisms involving vasculature (<i>i.e.</i> endothelial-to-mesenchymal transition, vascular remodelling, endothelial permeability, occult alveolar haemorrhage, vasoconstriction and hypoxia) and the genetic basis of vascular remodelling are described. The prevalence and clinical relevance of associated PH are highlighted with focus on the vasculature as a prognostic marker. The vascular effects of current antifibrotic therapies, the role of pulmonary vasodilators in the treatment of disease, and new pharmacological options with vascular-targeted activity are described.</p><p><strong>Conclusions: </strong>The vasculature plays a key role in the natural history of IPF from the early phases of disease until development of PH in a subgroup of patients, a complication related to a worse prognosis. Pulmonary vascular volume has emerged as a novel computed tomography finding and a predictor of mortality, independent of PH. New pharmacological options with concomitant vascular-directed activity might be promising in the treatment of IPF.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"10 6","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587140/pdf/","citationCount":"0","resultStr":"{\"title\":\"Vascular involvement in idiopathic pulmonary fibrosis.\",\"authors\":\"Michele Mondoni, Rocco Rinaldo, Christopher J Ryerson, Cristina Albrici, Andrea Baccelli, Claudio Tirelli, Francesca Marchetti, Jacopo Cefalo, Giulia Nalesso, Giulia Ferranti, Fausta Alfano, Giovanni Sotgiu, Marco Guazzi, Stefano Centanni\",\"doi\":\"10.1183/23120541.00550-2024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing and progressive interstitial lung disease of unknown aetiology with a pathogenesis still partly unknown. Several microvascular and macrovascular abnormalities have been demonstrated in the pathogenesis of IPF and related pulmonary hypertension (PH), a complication of the disease.</p><p><strong>Methods: </strong>We carried out a non-systematic, narrative literature review aimed at describing the role of the vasculature in the natural history of IPF.</p><p><strong>Results: </strong>The main molecular pathogenetic mechanisms involving vasculature (<i>i.e.</i> endothelial-to-mesenchymal transition, vascular remodelling, endothelial permeability, occult alveolar haemorrhage, vasoconstriction and hypoxia) and the genetic basis of vascular remodelling are described. The prevalence and clinical relevance of associated PH are highlighted with focus on the vasculature as a prognostic marker. The vascular effects of current antifibrotic therapies, the role of pulmonary vasodilators in the treatment of disease, and new pharmacological options with vascular-targeted activity are described.</p><p><strong>Conclusions: </strong>The vasculature plays a key role in the natural history of IPF from the early phases of disease until development of PH in a subgroup of patients, a complication related to a worse prognosis. Pulmonary vascular volume has emerged as a novel computed tomography finding and a predictor of mortality, independent of PH. New pharmacological options with concomitant vascular-directed activity might be promising in the treatment of IPF.</p>\",\"PeriodicalId\":11739,\"journal\":{\"name\":\"ERJ Open Research\",\"volume\":\"10 6\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-11-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587140/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ERJ Open Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1183/23120541.00550-2024\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ERJ Open Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/23120541.00550-2024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

背景:特发性肺纤维化(IPF)是一种慢性、纤维化和进行性间质性肺病,病因不明,部分发病机制尚不清楚。在 IPF 及其并发症肺动脉高压(PH)的发病机制中,已证实存在多种微血管和大血管异常:方法:我们进行了一项非系统性的叙述性文献综述,旨在描述血管在 IPF 自然病史中的作用:结果:描述了涉及血管的主要分子致病机制(即内皮-间质转化、血管重塑、内皮通透性、隐匿性肺泡出血、血管收缩和缺氧)以及血管重塑的遗传基础。重点介绍了相关 PH 的发病率和临床意义,并将血管作为预后标志。此外,还介绍了当前抗纤维化疗法对血管的影响、肺血管扩张剂在疾病治疗中的作用以及具有血管靶向活性的新药物选择:血管在 IPF 的自然病史中发挥着关键作用,从疾病的早期阶段直到亚组患者出现 PH,这是一种与预后恶化相关的并发症。肺血管容积已成为计算机断层扫描的一项新发现,也是预测死亡率的一个指标,与 PH 无关。在治疗 IPF 的过程中,同时具有血管导向活性的新药物疗法可能会大有可为。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Vascular involvement in idiopathic pulmonary fibrosis.

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing and progressive interstitial lung disease of unknown aetiology with a pathogenesis still partly unknown. Several microvascular and macrovascular abnormalities have been demonstrated in the pathogenesis of IPF and related pulmonary hypertension (PH), a complication of the disease.

Methods: We carried out a non-systematic, narrative literature review aimed at describing the role of the vasculature in the natural history of IPF.

Results: The main molecular pathogenetic mechanisms involving vasculature (i.e. endothelial-to-mesenchymal transition, vascular remodelling, endothelial permeability, occult alveolar haemorrhage, vasoconstriction and hypoxia) and the genetic basis of vascular remodelling are described. The prevalence and clinical relevance of associated PH are highlighted with focus on the vasculature as a prognostic marker. The vascular effects of current antifibrotic therapies, the role of pulmonary vasodilators in the treatment of disease, and new pharmacological options with vascular-targeted activity are described.

Conclusions: The vasculature plays a key role in the natural history of IPF from the early phases of disease until development of PH in a subgroup of patients, a complication related to a worse prognosis. Pulmonary vascular volume has emerged as a novel computed tomography finding and a predictor of mortality, independent of PH. New pharmacological options with concomitant vascular-directed activity might be promising in the treatment of IPF.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ERJ Open Research
ERJ Open Research Medicine-Pulmonary and Respiratory Medicine
CiteScore
6.20
自引率
4.30%
发文量
273
审稿时长
8 weeks
期刊介绍: ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信